Cangrelor

P2Y12 Platelet Inhibitor — BLOOD AND BLOOD FORMING ORGANS

Key facts

Cangrelor is an ofp drug in the P2Y12 Platelet Inhibitor class catalogued in DrugCentral. It was first approved by the EMA in 2015. Its mechanism of action is classified as P2Y12 Receptor Antagonists. DrugCentral lists 3 molecular targets, including Gpr17, P2RY12 and P2RY13. Recorded indications include Percutaneous coronary intervention.

• Approval status: ofp (first approved 2015 by the EMA).
• Drug class: P2Y12 Platelet Inhibitor.
• Mechanism of action: P2Y12 Receptor Antagonists.
• Molecular targets: Gpr17, P2RY12 and P2RY13 (3 listed in DrugCentral).
• Indications: Percutaneous coronary intervention.
• ATC code: B01AC25 (Platelet aggregation inhibitors excl. heparin).
• Molecular formula: C17H25Cl2F3N5O12P3S2; molecular weight 776.37 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Percutaneous coronary intervention

Mechanism & targets

• Mechanism of action (MoA): P2Y12 Receptor Antagonists
• Established pharmacologic class: P2Y12 Platelet Inhibitor

Molecular targets (3)

Target	Gene	Action	Activity
Uracil nucleotide/cysteinyl leukotriene receptor	Gpr17	antagonist	IC50 8.92
P2Y purinoceptor 12	P2RY12	antagonist	IC50 8.63
P2Y purinoceptor 13	P2RY13	antagonist	IC50 8.30

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2015-06-22	FDA	—	MEDICINES CO
2015-03-23	EMA	—	—

ATC classification

ATC code	Therapeutic hierarchy
B01AC25	BLOOD AND BLOOD FORMING ORGANS › ANTITHROMBOTIC AGENTS › ANTITHROMBOTIC AGENTS › Platelet aggregation inhibitors excl. heparin

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Off label use	256.2
Vascular stent thrombosis	209.3

Chemical structure

• Molecular formula: C₁₇H₂₅Cl₂F₃N₅O₁₂P₃S₂
• Molecular weight: 776.37 g/mol
• CAS number: —
• InChIKey: PAEBIVWUMLRPSK-IDTAVKCVSA-N
• PubChem CID: 9854012

CSCCNC1=NC(SCCC(F)(F)F)=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)C(Cl)(Cl)P(O)(O)=O)[C@@H](O)[C@H]1O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Cangrelor used for?

DrugCentral lists the following indications for Cangrelor: Percutaneous coronary intervention.

How does Cangrelor work?

Cangrelor is classified as P2Y12 Receptor Antagonists; its molecular targets in DrugCentral include Gpr17 (antagonist), P2RY12 (antagonist) and P2RY13 (antagonist).

When was Cangrelor first approved?

Cangrelor was first approved by the EMA in 2015.

What drug class does Cangrelor belong to?

Cangrelor is in the P2Y12 Platelet Inhibitor class.

What is the chemical formula of Cangrelor?

Cangrelor has the molecular formula C17H25Cl2F3N5O12P3S2 and a molecular weight of 776.37 g/mol.

Sources

• DrugCentral drug card 5006 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1097279 — compound record and bioactivity
• PubChem CID 9854012 — chemical identifiers
• DrugBank DB06441 — drug record
• FDA UNII 6AQ1Y404U7 — substance identity
• DailyMed: FDA labels for Cangrelor — current prescribing information (label search)
• UniProt Q9H244 (P2RY12) — target protein
• UniProt Q9BPV8 (P2RY13) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.